New Zealand clears first clinical trial of epigenetic editing for hepatitis B - Endpoints News

New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials. Led by Ed Gane at Auckland City Hospital, it's the second HBV genome-altering therapy to enter trials after Precision Biosciences' tAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute